SI1150712T1 - Pripravek cepiva proti humanem papiloma virusu - Google Patents

Pripravek cepiva proti humanem papiloma virusu

Info

Publication number
SI1150712T1
SI1150712T1 SI200031009T SI200031009T SI1150712T1 SI 1150712 T1 SI1150712 T1 SI 1150712T1 SI 200031009 T SI200031009 T SI 200031009T SI 200031009 T SI200031009 T SI 200031009T SI 1150712 T1 SI1150712 T1 SI 1150712T1
Authority
SI
Slovenia
Prior art keywords
papilloma virus
virus vaccine
human papilloma
vaccine formulations
formulations
Prior art date
Application number
SI200031009T
Other languages
English (en)
Inventor
David B Volkin
Li Shi
Henryk Mach
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SI1150712T1 publication Critical patent/SI1150712T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI200031009T 1999-02-05 2000-02-01 Pripravek cepiva proti humanem papiloma virusu SI1150712T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05
EP00905886A EP1150712B1 (en) 1999-02-05 2000-02-01 Human papilloma virus vaccine formulations
PCT/US2000/002463 WO2000045841A2 (en) 1999-02-05 2000-02-01 Human papilloma virus vaccine formulations

Publications (1)

Publication Number Publication Date
SI1150712T1 true SI1150712T1 (sl) 2009-02-28

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200031009T SI1150712T1 (sl) 1999-02-05 2000-02-01 Pripravek cepiva proti humanem papiloma virusu

Country Status (15)

Country Link
US (1) US6251678B1 (sl)
EP (1) EP1150712B1 (sl)
JP (2) JP4841726B2 (sl)
KR (1) KR20010093290A (sl)
AR (1) AR022510A1 (sl)
AT (1) ATE413188T1 (sl)
AU (1) AU764138B2 (sl)
CA (1) CA2361837C (sl)
CY (1) CY1108702T1 (sl)
DE (1) DE60040727D1 (sl)
DK (1) DK1150712T3 (sl)
ES (1) ES2313881T3 (sl)
PT (1) PT1150712E (sl)
SI (1) SI1150712T1 (sl)
WO (1) WO2000045841A2 (sl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU4346101A (en) * 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
ES2644275T3 (es) * 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PL371261A1 (en) * 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
AU2003213065A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
AU2003293942B2 (en) * 2002-12-20 2009-12-10 Glaxosmithkline Biologicals Sa HPV-16 and -18 L1 VLP vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
CA2551896A1 (en) 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
BRPI0516476A (pt) * 2004-10-05 2008-09-02 Cytos Biotechnology Ag conjugados de antìgeno de vlp e seu uso como vacinas
WO2006037787A2 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
AU2006220835B2 (en) * 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US7955603B2 (en) 2006-09-29 2011-06-07 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EP2258380B1 (en) 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nucleic acid for imparting heat resistance to lactoferrin
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
ES2762230T3 (es) 2011-06-24 2020-05-22 Merck Sharp & Dohme Formulaciones de vacuna contra el HPV que comprenden un adyuvante de aluminio y métodos de producción de las mismas
AU2012282658B2 (en) * 2011-07-11 2014-11-27 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
CA2859916C (en) 2012-01-09 2021-02-09 Sanofi Pasteur Biologics, Llc Purification of herpes virus
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
EP2852662B1 (en) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
JP6014666B2 (ja) 2012-06-20 2016-10-25 国立大学法人 東京大学 粘膜免疫賦活化剤及びｈｐｖ感染症治療用経口医薬組成物
WO2014100853A1 (en) * 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2015114506A2 (en) 2014-01-31 2015-08-06 Marini Bruna Biosensor for the determination of infections and associated pathologies
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
WO2017173371A1 (en) 2016-04-01 2017-10-05 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
KR20200083540A (ko) * 2017-11-01 2020-07-08 머크 샤프 앤드 돔 코포레이션 시토메갈로바이러스의 안정한 제형
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ATE377428T1 (de) * 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
DK0973546T3 (da) * 1997-04-08 2004-06-28 Merck & Co Inc Stabiliserede formuleringer med human papillomavirus

Also Published As

Publication number Publication date
EP1150712A2 (en) 2001-11-07
DK1150712T3 (da) 2009-02-02
DE60040727D1 (de) 2008-12-18
PT1150712E (pt) 2008-12-22
AR022510A1 (es) 2002-09-04
JP2011225578A (ja) 2011-11-10
US6251678B1 (en) 2001-06-26
WO2000045841A3 (en) 2000-12-14
ES2313881T3 (es) 2009-03-16
EP1150712B1 (en) 2008-11-05
CA2361837C (en) 2011-06-07
WO2000045841A2 (en) 2000-08-10
KR20010093290A (ko) 2001-10-27
JP4841726B2 (ja) 2011-12-21
AU2749200A (en) 2000-08-25
JP2002536340A (ja) 2002-10-29
AU764138B2 (en) 2003-08-14
CY1108702T1 (el) 2013-09-04
CA2361837A1 (en) 2000-08-10
ATE413188T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
PT1150712E (pt) Formulações para a vacina do vírus do papiloma humano
IL158107A0 (en) Human papillomaviruses vaccine
HUP0301308A3 (en) Human papilloma virus treatment
PL392363A1 (pl) Kompozycja szczepionki
IL145043A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
IL150961A0 (en) Human immunodeficiency virus vaccine
HUP0202770A3 (en) Human papilloma virus vaccine
GB9915204D0 (en) Vaccine
GB9906437D0 (en) Vaccine
GB9925432D0 (en) Virus preparation
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
GB9911824D0 (en) New vaccine formulations
GB9911825D0 (en) New vaccine formulations
GB9909072D0 (en) Vaccine
GB0008029D0 (en) New vaccine formulations
SI1296711T1 (sl) HPV-E7 za zdravljenje humanih papilomavirusnih infekcij
GB9925434D0 (en) Virus Preparation
GB9917981D0 (en) Viral vaccine
GB9922703D0 (en) Vaccine
GB9904408D0 (en) Vaccine
GB9922701D0 (en) Vaccine
GB9927336D0 (en) Vaccine
GB9904412D0 (en) Vaccine